CN1308009C - 具有调节血压功能的保健品 - Google Patents
具有调节血压功能的保健品 Download PDFInfo
- Publication number
- CN1308009C CN1308009C CNB2005100642254A CN200510064225A CN1308009C CN 1308009 C CN1308009 C CN 1308009C CN B2005100642254 A CNB2005100642254 A CN B2005100642254A CN 200510064225 A CN200510064225 A CN 200510064225A CN 1308009 C CN1308009 C CN 1308009C
- Authority
- CN
- China
- Prior art keywords
- present
- blood pressure
- health
- pressure regulation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000036541 health Effects 0.000 title claims description 13
- 230000036772 blood pressure Effects 0.000 title description 3
- 230000001105 regulatory effect Effects 0.000 title 1
- 230000029865 regulation of blood pressure Effects 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241001251068 Formica fusca Species 0.000 claims description 12
- 241001620634 Roger Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 abstract description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract description 8
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 abstract description 7
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 abstract description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract description 4
- 235000019253 formic acid Nutrition 0.000 abstract description 4
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 241000257303 Hymenoptera Species 0.000 abstract 3
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000006651 lactation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002213 flavones Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- -1 triterpenoid compound Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种具有调节血压功能的保健品，按重量份配比，它所含的活性成分的制备原料包含：杜仲0.1-10份，葛根0.1-10份，蚂蚁1份。本发明蚂蚁为拟黑多刺蚁。本发明最佳剂型是一种颗粒剂胶囊，经检测，本发明每100g含：甲酸1.58mg，葛根素5.0g，本发明具有调节血压功能的保健品具有调节血压的功能，适宜于血压偏高者，不适宜于孕妇及哺乳期妇女、婴幼儿、少年儿童及异体蛋白过敏者，按常规中药颗粒剂胶囊方法制备，每粒胶囊含药量为0.4g，用法用量：一次2-3粒，每日三次。本发明只是一种保健食品，不能替代药物。
Description
【技术领域】
本发明涉及一种保健食品，具体地说，涉及一种具有调节血压功能的保健品。
【背景技术】
现在，人们生活压力普遍加大，生活节奏加快，竞争日益激烈，高血压患者越来越多，通常所指的血压是血液在血管中流动时对血管壁产生的侧压。当动脉血管中血液粘稠度过高，血流的阻力就会增大，导致血流过缓，使脂类物质在血管壁上产生沉积，诱发动脉粥样硬化，使血管变窄，血管硬化，导致高血压。
中国传统注重药食同源，药食同源的保健食品越来越多地受到现代人的青睐。如何向广大消费者提供一种纯天然中药制备的、没有任何毒副作用的，药食同源的具有调节血压的保健功能的保健食品成为当今医学的新课题。
【发明内容】
本发明需要解决的技术问题就在于提供一种纯中药制剂的保健食品，它具有调节血压的保健功能。
为解决上述问题，本发明采用如下技术方案：
本发明具有调节血压功能的保健品，按重量份配比，它所含的活性成分的制备原料包含：杜仲0.1-10份，葛根0.1-10份，蚂蚁1份。
优选地，本发明具有调节血压功能的保健品按重量份配比，它所含的活性成分的制备原料包含：杜仲0.1-1份，葛根0.1-1份，蚂蚁1份。
或按重量份配比，它所含的活性成分的制备原料包含：杜仲0.5份，葛根0.5份，蚂蚁1份。
或按重量份配比，它所含的活性成分的制备原料包含：杜仲1-10份，葛根1-10份，蚂蚁1份。
或按重量份配比，它所含的活性成分的制备原料包含：杜仲1份，葛根1份，蚂蚁1份。
或按重量份配比，它所含的活性成分的制备原料包含：杜仲5份，葛根5份，蚂蚁1份。
优选地，本发明所述蚂蚁为拟黑多刺蚁。
优选地，本发明具有调节血压功能的保健品它是颗粒剂胶囊。
本发明基于祖国医学对保健食品的认识和治疗原则，吸取现代研究成绩，从中药中筛选出具有调节血压的保健功能的天然植物药，按中药理论组方。
本发明中，杜仲，又名思仙、思仲、木棉、丝连皮、红楝树皮。它是落叶乔木杜仲树上割下的树皮，按一定方法和规格加工成的一种名贵药材。
杜仲药用价值高，配方较宽，除有持续高效降压作用外，还能安胎、补肝肾、强筋骨；服用杜仲可治腰脊酸痛、小便余沥、阴下湿痒、胎漏欲坠等病症。经临床诊断鉴定证明，该药尤以治疗早期高血压及小儿麻痹后遗症最有效。
本发明中，葛根为豆科植物葛Pueraria lobata(Willd.)Ohwi的根。其根中主要含有的成分：1.多种异黄酮：大豆甙、大豆甙元、葛根素等；2.葛根甙A、B、C；3.三萜类：主要以葛皂醇A、B、C命名的7种新型齐墩果烷型醇类化合物；4.生物碱类。
葛根水煎剂、醇浸膏、总黄酮、葛根素均有明显的扩张冠状血管的作用。正常狗静注30mg/kg总黄酮，其冠脉血流量增加40％，血管阻力降低29％，且这种作用随剂量的增加而增加；总黄酮亦能对抗垂体后叶素引起的大鼠急性心肌缺血。葛根素的作用要强于总黄酮。从急性心肌缺血狗的右室旁路静注葛根素15～20mg/kg/min，连续15min可使进入缺血区冠脉侧枝血流量增加，非缺血区冠脉血流量亦增加。利血平给药后，总黄酮和葛根素对冠脉循环的作用仍保持，表明其作用是对血管平滑肌的直接松弛作用。
本发明中，蚂蚁，又名蚍蜉，药用名称为“玄驹”，属完全变态的昆虫。蚂蚁性味咸、平、有毒性。药用价值较高，蚂蚁的药用价值较高，具有抗风湿、抗炎、杀菌、抑菌、抗癌、抗过敏、护肝、平喘、镇痛、镇静、壮阳、滋阴、解毒等功能。对类风湿性关节炎、风湿性关节炎、恶性肿瘤、慢性肝炎、肺结核、阳萎、病后脱发、神经官能症等均有良好的医疗效果。
本发明优选的拟黑多刺蚁作为传统养生资源，文字记载已有三千多年的历史。拟黑多刺蚁含有丰富的蛋白质，其含量高达40％-55％，少数可达67％以上。其所含19种氨基酸中，有8种是人体必需氨基酸即：苏氨酸、苯丙氨酸、缬氨酸、异亮氨酸、亮氨酸、棘氨酸、蛋氨酸、色氨酸等。并含维生素A、维生素B1、B2、B12和C、D、E和钙、铁、铬、镁、锌、碘、硒等28种微量元素，其中以锌的含量最多，达到每千克含锌230mg-280mg。最为特别的是拟黑多刺蚁含有多种酶类和辅酶、草体蚁酸、淄族类化合物、三萜类化合物、蚁酸，同时含有大量的高能磷化物ATP，《本草纲目》记载；拟黑多刺蚁“扶正祛邪、补肾强身、活血化淤、延年益寿。食之益气力、泽颜色。”《中药大词典》记载，拟黑多刺蚁对抗衰老有奇效。
拟黑多刺蚁的主要功能有：
1、骨关节疾病：类风湿、风湿性关节炎、肩周炎、腰腿痛。
2、心脑血管疾病：冠心病、脑血栓后遗症、心绞痛、心肌炎。
3、泌尿系统疾病：肾炎、阳痿、早泄、性冷淡。
4、消化系统疾病：胃炎、消化不良、胆囊炎、肝炎、肝腹水、肝硬化。
5、神经系统疾病：神经衰弱、植物神经功能紊乱、失眠、头痛。
6、其他疾病：糖尿病、红斑狼疮、硬皮病、少白头、牙齿脱落、癌症术后。
本发明的上述组方可以直接研磨成粉或经过本领域常规提取技术如水提醇沉法或醇提水沉法的提取精制作为其活性成分。所述活性成分可以与药学上可接受的载体或赋型剂组合制成各种药学剂型如散剂、片剂、口服液、颗粒剂、注射剂、胶囊剂等等。其中所述的药学上可接受的载体或赋型剂根据不同的剂型而选择。所用的这些载体或赋型剂对于制药领域的普通技术人员是可以决定的。
本发明最佳剂型是一种颗粒剂胶囊，经检测，本发明每100g含：甲酸1.58mg，葛根素5.0g，本发明具有调节血压功能的保健品具有调节血压的功能，适宜于血压偏高者，不适宜于孕妇及哺乳期妇女、婴幼儿、少年儿童及异体蛋白过敏者，按常规中药颗粒剂胶囊方法制备，每粒胶囊含药量为0.4g，用法用量：一次2-3粒，每日三次。本发明只是一种保健食品，不能替代药物。
【具体实施方式】
现结合具体实施例对本发明进一步说明如下：
1、按下表中所列重量配比称取本发明所需原料，单位：kg
| 杜仲 | 葛根 | 拟黑多刺蚁 | |
| 实施例1 | 0.1 | 0.1 | 1 |
| 实施例2 | 0.5 | 0.5 | 1 |
| 实施例3 | 1 | 1 | 1 |
| 实施例4 | 5 | 5 | 1 |
| 实施例5 | 10 | 10 | 1 |
2、制备实施例
按上表内各实施例中原料配比，按照常规颗粒剂胶囊的制备方法制备成颗粒剂胶囊记得蚁力神依欣胶囊。
Claims (3)
1、一种具有调节血压功能的保健品，其特征在于它所含的活性成分的制备原料重量份配比为：杜仲0.5份，葛根0.5份，蚂蚁1份。
2、如权利要求1所述的具有调节血压功能的保健品，其特征在于所述蚂蚁为拟黑多刺蚁。
3、如权利要求1或2所述的具有调节血压功能的保健品，其特征在于它是颗粒剂胶囊。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100642254A CN1308009C (zh) | 2005-04-11 | 2005-04-11 | 具有调节血压功能的保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100642254A CN1308009C (zh) | 2005-04-11 | 2005-04-11 | 具有调节血压功能的保健品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686395A CN1686395A (zh) | 2005-10-26 |
| CN1308009C true CN1308009C (zh) | 2007-04-04 |
Family
ID=35304437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100642254A Expired - Fee Related CN1308009C (zh) | 2005-04-11 | 2005-04-11 | 具有调节血压功能的保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1308009C (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102172385B (zh) * | 2011-01-12 | 2016-02-24 | 涂传荣 | 一种具有增强免疫力、降血糖和降血脂作用的中药制剂 |
| CN103461880A (zh) * | 2013-08-13 | 2013-12-25 | 当涂县瑞龙果树种植专业合作社 | 一种降血压的南瓜片 |
| CN106166169A (zh) * | 2016-08-17 | 2016-11-30 | 崔明华 | 一种双向调节血压的药物及其生产方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106674A (zh) * | 1994-10-13 | 1995-08-16 | 汪志伟 | 启痹愈瘫中药 |
| CN1433787A (zh) * | 2002-01-19 | 2003-08-06 | 马献山 | 一种祛风湿、止痹痛的内服、外用药 |
-
2005
- 2005-04-11 CN CNB2005100642254A patent/CN1308009C/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106674A (zh) * | 1994-10-13 | 1995-08-16 | 汪志伟 | 启痹愈瘫中药 |
| CN1433787A (zh) * | 2002-01-19 | 2003-08-06 | 马献山 | 一种祛风湿、止痹痛的内服、外用药 |
Non-Patent Citations (3)
| Title |
|---|
| 益本昌药酒的研制临床应用与微量元素测定 戚建国等，广东微量元素科学，第6卷第5期 1999 * |
| 蚂蚁制剂药理研究的新进展 何颖等，时珍国医国药，第14卷第2期 2003 * |
| 蚂蚁制剂药理研究的新进展 何颖等，时珍国医国药，第14卷第2期 2003;益本昌药酒的研制临床应用与微量元素测定 戚建国等，广东微量元素科学，第6卷第5期 1999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686395A (zh) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103877263B (zh) | 一种红参、玛咖、绿茶提取物(茶氨酸)等复合中药抗疲劳养生制剂 | |
| CN102630790B (zh) | 一种银杏叶苦荞茶及其制备工艺 | |
| CN100379439C (zh) | 一种增免安神保健品 | |
| CN102920806B (zh) | 安神降压中药茶 | |
| CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
| CN103479754B (zh) | 降压药及其制备方法 | |
| CN1308009C (zh) | 具有调节血压功能的保健品 | |
| CN105287780A (zh) | 一种植物饮料及其制备方法 | |
| CN1060028C (zh) | 一种主要由谷物瓜菜果组成的健康食品 | |
| CN103100028A (zh) | 有利于降低酒精性肝损伤危害的软胶囊及其制备方法 | |
| CN1314423C (zh) | 可调节血压和血脂、防治心脑血管疾病的葛胶囊 | |
| CN102228596B (zh) | 一种药物组合物及制剂及在治疗冠心病、心绞痛中的应用 | |
| CN1799582A (zh) | 降血糖、降血压的药物 | |
| CN109528827B (zh) | 一种活血祛瘀、降血脂的药物组合物、制剂及其制备方法 | |
| CN1279949C (zh) | 一种轻身益寿中药 | |
| CN1321484A (zh) | 治疗冠心病合并高血压的药品及制备工艺 | |
| CN1686396A (zh) | 具有耐缺氧功能的保健品 | |
| CN101172155A (zh) | 生脉温胆汤新剂型及其生产方法 | |
| CN113456778A (zh) | 一种提升能量的组合物及其制备方法 | |
| CN106177634A (zh) | 一种减肥瘦身复方制剂及其制备方法 | |
| CN1686397A (zh) | 具有益肝功能的保健食品 | |
| CN1308016C (zh) | 滋补酒 | |
| CN114515009B (zh) | 一种具有减肥降脂功效的组合物及其应用 | |
| CN101073409A (zh) | 药食多效保健品 | |
| CN1810268A (zh) | 一种治疗中风的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |